Purdue Pharma says it will acquire from VM Pharma full worldwide development and commercial rights to a first-in-class, allosteric selective tropomyosin receptor kinase A (TrkA) inhibitor program to treat chronic pain, led by the Phase II-ready VM-902A. The deal could generate up to $213 million-plus for VM Pharma.

VM-902A is an orally bioavailable, peripherally acting and allosteric inhibitor of protein kinase TrkA, the high affinity receptor of nerve growth factor. VM-902A was successfully tested in single and multiple ascending dose trials on 72 patients during Phase I clinical trials.